+1 800 783 4636

UC-II Peal

UC-II J Vet Pharmacol Ther. 2007 Jun;30(3):275-8. Therapeutic efficacy and safety of undenatured type-II collagen (UC-II) alone or in combination with (-)-hydroxycitric acid and chromemate in arthritic dogs. Peal A1, D’Altilio M, Simms C, Alvey M, Gupta RC, Goad JT, Canerdy TD, Bagchi M, Bagchi D. Abstract The present investigation evaluated therapeutic efficacy and safety of glycosylated undenatured type II collagen (active UC-II) alone or in combination with (-)-hydroxycitric acid (HCA-SX, SuperCitrimax) and ChromeMate (chromium niacinate, CM). Twenty five arthritic dogs in five groups (n = 5) received daily treatment as follows: group I (placebo), group II (10 mg active UC-II), group III (1800 mg HCA-SX), group IV (1800 mg HCA-SX + 100 mg CM), and group V (1800 mg HCA-SX + 100 mg CM +10 mg active UC-II). The treatment was given daily for 120 days, followed by 30 days withdrawal. The dogs were evaluated for overall pain, pain upon limb manipulation, and exercise-associated lameness, on a monthly basis. Blood-serum samples were assayed for markers of liver [bilirubin and alanine aminotransferase (ALT)] and renal [blood urea nitrogen (BUN) and creatinine] functions. Group I dogs exhibited no significant change in arthritic conditions. The dogs receiving active UC-II alone (group II) […] Read More

Zychrome Sreejayan

Zychrome® Toxicol Mech Methods. 2010 Jul;20(6):321-33. doi: 10.3109/15376516.2010.487880. Safety and toxicological evaluation of a novel chromium(III) dinicocysteinate complex. Sreejayan N1, Marone PA, Lau FC, Yasmin T, Bagchi M, Bagchi D. Abstract Chromium(III) is an essential trace element required for normal protein, fat and carbohydrate metabolism. It also helps in energy production and increasing lean body mass. Chromium(III) dinicocysteinate (CDNC) is a unique form of bioavailable chromium(III). This study was focused on determining the broad spectrum safety of CDNC. Acute oral, acute dermal, primary dermal and eye irritation studies, Ames’ bacterial reverse mutation assay, mammalian erythrocyte micronucleus test, and a 90-day dose-dependent oral toxicity study were conducted. Acute oral and dermal LD(50) of CDNC was found to be greater than 2000 mg/kg in Sprague-Dawley rats. A primary skin irritation study in New Zealand Albino rabbits demonstrated CDNC as slightly irritating. An eye irritation study exhibited that CDNC is moderately irritating. Ames’ bacterial reverse mutation assay and mammalian erythrocyte micronucleus test demonstrated CDNC as non-mutagenic. A dose-dependent 90-day oral toxicity study demonstrated no significant toxicity of CDNC. Body weight, food and water consumption, selected organ weights (expressed as percentages of body or brain weights), ocular health, hematology, blood chemistry, and histopathology showed […] Read More